Vorapaxar: Difference between revisions
(New page: Vorapaxar (previously known as SCH 530348) is an himbacine derivative but completely lacks the muscarinic M2 antagonist activity characteristic of himbacine. This agent is a potent, rever...) |
No edit summary |
||
| Line 1: | Line 1: | ||
Vorapaxar (previously known as SCH 530348) is | '''Vorapaxar''' (previously known as SCH 530348; Merck,Sharp & Dome, USA) is structurally similar to the natural product himbacine, but completely lacks the muscarinic M2 antagonist activity characteristic of himbacine. | ||
This agent is | This agent is an '''orally-active''', potent, reversible, and selective '''inhibitor''' of the '''PAR-1 receptor''' with a '''very long''' terminal '''half-life''', which ranges from 126 to 269 h. Although reversible, vorapaxar dissociates very slowly from the PAR-1 receptor, which is a critical requirement to compete effectively with the resident tethered ligand. | ||
Vorapaxar is a '''direct acting drug''' (thus not a pro-drug) and is '''inactivated''' mainly '''via the CYP3A4 enzymatic system'''. Vorapaxar has '''no significant renal metabolism'''. | |||
The key phase II study with vorapaxar was the TRA-PCI, a large phase II study that tested the safety and preliminary efficacy of this agent in 1,030 patients with stable CAD presumed to be managed with PCI. In this study bleeding as measured by the TIMI scale (major or minor) was similar between placebo and the 3 doses tested of vorapaxar (0.5, 1, and 2.5 mg). Exploratory analysis on efficacy also showed a numerical reduction in the myocardial infarction component, mainly related to PCI. | |||
A similarly designed study was conducted in Japan in patients with | ==Phase II of Vorapaxar: TRA-PCI and Japanese study == | ||
The key phase II study with vorapaxar was the '''TRA-PCI''', a large phase II study that tested the safety and preliminary efficacy of this agent in 1,030 patients with stable CAD presumed to be managed with PCI. In this study bleeding as measured by the TIMI scale (major or minor) was similar between placebo and the 3 doses tested of vorapaxar (0.5, 1, and 2.5 mg). Exploratory analysis on efficacy also showed a numerical reduction in the myocardial infarction component, mainly related to PCI. | |||
A similarly designed study was conducted in Japan in patients with [[NSTEACS]] invasively managed. This additional phase II study in Japanese patients had similar results compared with TRA-PCI. Specifically, this study showed a similar incidence of bleeding between placebo and vorapaxar and a reduction of MIs with vorapaxar. | |||
==External Links== | |||
* {{cite journal | author = Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators | title = Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. | journal = Lancet | volume = 373 | issue = 9667 | pages = 919-28 | year = 2009 | id = PMID 19286091}} | |||
* {{cite journal | author = Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. | title = Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. | journal = J Atheroscler Thromb | volume = 17 | issue = 2 | pages = 156-64 | year = 2010 | id = PMID 20124733}} | |||
Revision as of 21:52, 25 October 2010
Vorapaxar (previously known as SCH 530348; Merck,Sharp & Dome, USA) is structurally similar to the natural product himbacine, but completely lacks the muscarinic M2 antagonist activity characteristic of himbacine.
This agent is an orally-active, potent, reversible, and selective inhibitor of the PAR-1 receptor with a very long terminal half-life, which ranges from 126 to 269 h. Although reversible, vorapaxar dissociates very slowly from the PAR-1 receptor, which is a critical requirement to compete effectively with the resident tethered ligand.
Vorapaxar is a direct acting drug (thus not a pro-drug) and is inactivated mainly via the CYP3A4 enzymatic system. Vorapaxar has no significant renal metabolism.
Phase II of Vorapaxar: TRA-PCI and Japanese study
The key phase II study with vorapaxar was the TRA-PCI, a large phase II study that tested the safety and preliminary efficacy of this agent in 1,030 patients with stable CAD presumed to be managed with PCI. In this study bleeding as measured by the TIMI scale (major or minor) was similar between placebo and the 3 doses tested of vorapaxar (0.5, 1, and 2.5 mg). Exploratory analysis on efficacy also showed a numerical reduction in the myocardial infarction component, mainly related to PCI. A similarly designed study was conducted in Japan in patients with NSTEACS invasively managed. This additional phase II study in Japanese patients had similar results compared with TRA-PCI. Specifically, this study showed a similar incidence of bleeding between placebo and vorapaxar and a reduction of MIs with vorapaxar.
External Links
- Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA; TRA-PCI Investigators (2009). "Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study". Lancet. 373 (9667): 919–28. PMID 19286091.
- Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. (2010). "Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome". J Atheroscler Thromb. 17 (2): 156–64. PMID 20124733.